Properdin deficiency

Common Name(s)

Properdin deficiency

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Properdin deficiency" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Properdin deficiency" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Properdin deficiency" returned 11 free, full-text research articles on human participants. First 3 results:

Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.
 

Author(s): Allison M Lesher, Lin Zhou, Yuko Kimura, Sayaka Sato, Damodar Gullipalli, Andrew P Herbert, Paul N Barlow, Hannes U Eberhardt, Christina Skerka, Peter F Zipfel, Takayuki Hamano, Takashi Miwa, Kenneth S Tung, Wen-Chao Song

Journal: J. Am. Soc. Nephrol.. 2013 Jan;24(1):53-65.

 

Factor H (fH) and properdin both modulate complement; however, fH inhibits activation, and properdin promotes activation of the alternative pathway of complement. Mutations in fH associate with several human kidney diseases, but whether inhibiting properdin would be beneficial in ...

Last Updated: 31 Dec 1969

Go To URL
Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.
 

Author(s): Marieta M Ruseva, Katherine A Vernon, Allison M Lesher, Wilhelm J Schwaeble, Youssif M Ali, Marina Botto, Terence Cook, Wenchao Song, Cordula M Stover, Matthew Caleb Pickering

Journal: J. Am. Soc. Nephrol.. 2013 Jan;24(1):43-52.

 

Complement factor H (CFH) is a negative regulator of the alternative pathway of complement, and properdin is the sole positive regulator. CFH-deficient mice (CFH(-/-)) develop uncontrolled C3 activation and spontaneous renal disease characterized by accumulation of C3 along the glomerular ...

Last Updated: 31 Dec 1969

Go To URL
A novel mutation W388X underlying properdin deficiency in a Finnish family.
 

Author(s): M Helminen, S Seitsonen, H Jarva, S Meri, I E Järvelä

Journal: Scand. J. Immunol.. 2012 Apr;75(4):445-8.

 

Properdin deficiency is a rare immunological disorder inherited as an X-chromosomal recessive trait. Properdin deficiency poses a significant risk for severe meningococcal infections. About 20 mutations have been reported to underlie properdin deficiency. Here we report a large Finnish ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Properdin deficiency" returned 1 free, full-text review articles on human participants. First 3 results:

Properdin deficiency and meningococcal disease--identifying those most at risk.
 

Author(s): S M Linton, B P Morgan

Journal: Clin. Exp. Immunol.. 1999 Nov;118(2):189-91.

 

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.